Ulrike Höckendorf

Ulrike Höckendorf

Auto-generated profile, based on publicly available information

Ulrike Höckendorf

Department of Internal Medicine III, Klinikum rechts der Isar, School of Medicine and Health, Technical University of Munich, München, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2022 in Oncogene
Verified
Journal Article
Open access
PDF file
AMAnna-Lena Meinhardt
Anna-Lena Meinhardt
EMEnkhtsetseg Munkhbaatar
Enkhtsetseg Munkhbaatar
UHUlrike Höckendorf
Ulrike Höckendorf
MDMichelle Dietzen
Michelle Dietzen
MDMarta Dechant
Marta Dechant
PJPhilipp J. Jost
Philipp J. Jost
A variety of cancer entities are driven by KRAS mutations, which remain difficult to target clinically. Survival pathways, such as resistance to cell death, may represent a promising treatment approach in KRAS mutated cancers. Based on the frequently observed genomic deletions of BCL-2-related ovarian killer (BOK) in cancer patients, we explored the function of BOK in a mutant KrasG12D-driven murine model of lung cancer. Using KrasG12D/+Bok−/− mice, we observed an overall tumor-promoting function of BOK in vivo. Specifically, loss of BOK reduced proliferation both in cell lines in vitro as well as in KrasG12D-driven tumor lesions in vivo. During tumor development in vivo, loss of BOK resulted in a lower tumor burden, with fewer, smaller, and less advanced tumors. Using KrasG12D/+Tp53Δ/ΔBok−/− mice, we identified that this phenotype was entirely dependent on the presence of functional p53. Furthermore, analysis of a human dataset of untreated early-stage lung tumors did not identify any common deletion of the BOK locus, independently of the TP53 status or the histopathological classification. Taken together our data indicate that BOK supports tumor progression in Kras-driven lung cancer.

26 November 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
UHUlrike Höckendorf
Ulrike Höckendorf
SDSayantanee Dutta
Sayantanee Dutta
AKArnold Kloos
Arnold Kloos
MRMarah Runtsch
Marah Runtsch
CZCarina Zötsch
Carina Zötsch
PJPhilipp J. Jost
Philipp J. Jost
Acute myeloid leukemia (AML) is characterized by frequent relapse, which is driven by resistant leukemic stem or progenitor cells (LSCs). Here, we reported on a tumor-suppressive mechanism that can be harnessed to simultaneously clear LSCs and promote healthy hematopoiesis. Genetic deletion of the tumor necrosis factor (TNF) superfamily member lymphotoxin alpha ( Lta ) blocked cell death and accelerated leukemogenesis in murine AML models. Accordingly, exposure of leukemic cells to exogenous recombinant lymphotoxin alpha (LTα 3 ) induced myeloid differentiation and, in part, cell death in AML progenitors. In syngeneic and patient-derived xenograft mouse models, exposure to recombinant LTα 3 resulted in deep and durable remissions. LTα 3 repressed leukemia by depleting tumor necrosis factor receptor (TNFR)–associated factor 2 (TRAF2) through activation of TNF receptors TNFR1 and TNFR2. In contrast with conventional therapies, LTα 3 exerted only minimal toxicity on the healthy hematopoiesis but instead promoted hematopoietic progenitors. Leveraging this endogenous tumor-suppressive mechanism may decouple treatment efficacy on malignant cells from undesired bone marrow suppression.